Innovation

Imagine being a researcher who is staring down not only a highly infectious virus, but one that’s caused the first global pandemic in more than 100 years. Meet Johnson & Johnson’s Hanneke Schuitemaker, Ph.D.

Johnson & Johnson has an expansive archive of existing drug compounds—and two researchers are leading the charge in combing through this molecular storehouse in pursuit of a possible breakthrough.

The article explores what guided the decision, which is just the latest example of our Chairman and CEO’s people-first approach to leadership at our healthcare company.

Roland Zahn, Ph.D., a Janssen scientist and expert in viral vaccines, was at the front lines of research during the Ebola outbreak. Today he and his team are working at record speed to help deliver a potential vaccine for the novel coronavirus.

Chairman & CEO Alex Gorsky shares that the company could have the first batches of a COVID-19 vaccine available for emergency-use authorization in early 2021—a substantially accelerated time frame in comparison to the typical vaccine development process.

Innovativeness and a commitment to social responsibility are just some of the respected attributes that helped the company land on the prestigious list for another year.

The company has committed to donate up to 500,000 doses of an investigational Janssen vaccine regimen to help protect citizens of the Democratic Republic of the Congo—the site of the world’s second largest outbreak of the disease.

The company just released its inaugural Diversity & Inclusion Impact Review. We take a look inside its pages to see how the company’s striving every day to build a culture of belonging.

As the IAS Conference on HIV Science kicks off in Mexico City, we explain how an investigational HIV vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson works—and how researchers hope to help change lives around the world with it.

Announced ahead of the International AIDS Society Conference on HIV Science in Mexico City, the new study will evaluate an investigational vaccine regimen in eight countries around the world for its ability to protect people from HIV infection.